临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Trelagliptin
中文名称:曲格列汀
CAS号:865759-25-7
分子式: C18H20FN5O2 分子量: 357.38
产品形式: free base
研发状态: Completed
研发用途: Type 2 Diabetes Mellitus
研究机构: Takeda
研发日期: August 7 2015
研发阶段: Phase 3
Trelagliptin (SYR-472), a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM, improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
Fostemsavir
CAS号:864953-29-7
分子式: C25H26N7O8P 分子量: 583.49
产品形式: Free Base
研发状态: Recruiting
研发用途: HIV Infections With Multi Drug Resistant Virus
研究机构: PENTA Foundation; ViiV Healthcare; PHPT Foundation; Hospital Universitario 12 de Octubre; Cromsource
研发日期: June 30 2022
研发阶段: Phase 1 : Phase 2
Fostemsavir (BMS-663068, Rukobia), the phosphonooxymethyl prodrug of BMS626529, is an attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells with EC50 of < 10 nM.
Resminostat
中文名称:马西替坦
CAS号:864814-88-0
分子式: C16H19N3O4S 分子量: 349.40
产品形式: free base
研发状态: Completed
研发用途: Cutaneous T Cell Lymphoma; Mycosis Fungoides; Sezary Syndrome
研究机构: 4SC AG
研发日期: October 12 2021
研发阶段: Phase 1
Resminostat (RAS2410) dose-dependently and selectively inhibits HDAC1/3/6 with IC50 of 42.5 nM/50.1 nM/71.8 nM, less potent to HDAC8 with IC50 of 877 nM.
Revefenacin
中文名称:瑞维那新
CAS号:864750-70-9
分子式: C35H43N5O4 分子量: 597.75
产品形式: Quinuclidinyl
研发状态: Completed
研发用途: Chronic Obstructive Pulmonary Disease (COPD)
研究机构: Mylan Inc.; Theravance Biopharma; Viatris Inc.
研发日期: Jun-15
研发阶段: Phase 1
Revefenacin (TD-4208, GSK-1160724) is a potent, lung-selective, long-acting muscarinic antagonist that may be for the treatment of respiratory disease.
Empagliflozin (BI 10773)
中文名称: 依帕列净
CAS号:864070-44-0
分子式: C23H27ClO7 分子量: 450.91
产品形式: free base
研发状态: Not yet recruiting
研发用途: Heart Failure
研究机构: Centre Hospitalier Universitaire Vaudois; Great Ormond Street Hospital for Children NHS Foundation Trust; University College London
研发日期: Aug-24
研发阶段: Phase 2
Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.
Fluconazole (UK 49858)
中文名称:氟康唑
CAS号:86386-73-4
分子式: C13H12F2N6O 分子量: 306.27
产品形式: free base
研发状态: Recruiting
研发用途: Invasive Fungal Infections
研究机构: Radboud University Medical Center
研发日期: October 18 2022
研发阶段: --
Fluconazole (Diflucan, Trican, Alfumet,UK 49858) is a fungal lanosterol 14 alpha-demethylase inhibitor, which thereby prevents the formation of ergosterol,used in the treatment and prevention of superficial and systemic fungal infections.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
